1,654 Shares in TransMedics Group, Inc. $TMDX Purchased by Verus Capital Partners LLC

Verus Capital Partners LLC acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 1,654 shares of the company’s stock, valued at approximately $222,000.

Several other hedge funds have also made changes to their positions in the company. Valmark Advisers Inc. increased its position in shares of TransMedics Group by 34.6% in the 2nd quarter. Valmark Advisers Inc. now owns 9,709 shares of the company’s stock valued at $1,301,000 after purchasing an additional 2,496 shares during the last quarter. Raymond James Financial Inc. grew its holdings in shares of TransMedics Group by 135.8% during the first quarter. Raymond James Financial Inc. now owns 145,393 shares of the company’s stock worth $9,782,000 after buying an additional 83,722 shares in the last quarter. Northern Trust Corp raised its stake in TransMedics Group by 2.1% during the first quarter. Northern Trust Corp now owns 361,963 shares of the company’s stock worth $24,353,000 after purchasing an additional 7,341 shares during the period. Montanaro Asset Management Ltd increased its holdings in TransMedics Group by 9.7% in the 1st quarter. Montanaro Asset Management Ltd now owns 153,675 shares of the company’s stock valued at $10,339,000 after purchasing an additional 13,640 shares in the last quarter. Finally, Wakefield Asset Management LLLP acquired a new stake in TransMedics Group during the 2nd quarter valued at approximately $1,179,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Activity

In other news, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total value of $540,323.90. Following the sale, the director directly owned 2,866 shares of the company’s stock, valued at $373,869.70. The trade was a 59.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 7.00% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on TMDX. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Jefferies Financial Group started coverage on TransMedics Group in a report on Monday, October 13th. They set a “buy” rating and a $145.00 target price on the stock. Piper Sandler decreased their target price on TransMedics Group from $145.00 to $140.00 and set an “overweight” rating for the company in a research note on Thursday, October 30th. Zacks Research lowered TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Finally, Stifel Nicolaus started coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They issued a “hold” rating and a $115.00 target price on the stock. Eight analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $130.73.

TransMedics Group Trading Up 0.5%

Shares of TransMedics Group stock traded up $0.60 during midday trading on Thursday, reaching $119.78. The company had a trading volume of 40,098 shares, compared to its average volume of 1,231,689. The firm has a market cap of $4.09 billion, a PE ratio of 48.20 and a beta of 2.05. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The stock has a fifty day moving average price of $118.37 and a 200 day moving average price of $119.45. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $145.50.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same period last year, the business posted $0.12 earnings per share. TransMedics Group’s revenue was up 32.2% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.